Innovent Biologics Inc., a biopharmaceutical company that develops, manufactures and commercializes medicines, has entered a ...

Roche is wasting no time in getting out its checkbook in 2025, signing a new biobucks-heavy pact that aims to add another new ...

Roche has once again returned to China to bolster its antibody-drug conjugate pipeline, this time striking a licensing deal ...

Chinese biotech Innovent Biologics (OTCPK:IVBIY) (OTCPK:IVBXF) has entered into a collaboration and licensing agreement with ...

In a deal valued at up to $1 billion, Roche has licensed rights to a DLL3-directed antibody-drug conjugate (ADC) from China's ...

Innovent Biologics and Roche have entered a partnership and exclusive licence agreement to accelerate the development of a ...

In separate DLL3 antibody-drug conjugate (ADC) deals, Roche licensed from Innovent Biologics and Ideaya reached for Hengrui.

Global markets have recently shown mixed performances, with the S&P 500 and Nasdaq Composite both closing out a strong year despite some volatility and profit-taking towards year-end. In this ...

Roche's strategic changes in drug development and M&A activity may drive future growth, despite recent setbacks in clinical ...

Innovent inks exclusive global license agreement with Roche to advance the development of IBI3009, a novel DLL3 targeted ADC candidate: San Francisco, US Friday, January 3, 2025, ...

Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high quality ...

IBI3009 is an ADC designed to target DLL3, a molecule overexpressed in certain cancers, mainly small-cell lung cancer. The collaboration aims to advance it for the benefit of patients with ...